Lantern Pharma Inc (LTRN) - Total Assets
Based on the latest financial reports, Lantern Pharma Inc (LTRN) holds total assets worth $13.63 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Lantern Pharma Inc shareholders equity for net asset value and shareholders' equity analysis.
Lantern Pharma Inc - Total Assets Trend (2018–2024)
This chart illustrates how Lantern Pharma Inc's total assets have evolved over time, based on quarterly financial data.
Lantern Pharma Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Lantern Pharma Inc's total assets of $13.63 Million consist of 98.7% current assets and 1.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 29.4% |
| Accounts Receivable | $97.00K | 0.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Lantern Pharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Lantern Pharma Inc (LTRN) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lantern Pharma Inc's current assets represent 98.7% of total assets in 2024, a decrease from 99.0% in 2018.
- Cash Position: Cash and equivalents constituted 29.4% of total assets in 2024, down from 99.0% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 0.4% of total assets.
Lantern Pharma Inc Competitors by Total Assets
Key competitors of Lantern Pharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Lantern Pharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.33 | 8.31 | 36.64 |
| Quick Ratio | 3.33 | 8.31 | 36.64 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $9.42 Million | $26.32 Million | $19.68 Million |
Lantern Pharma Inc - Advanced Valuation Insights
This section examines the relationship between Lantern Pharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.09 |
| Latest Market Cap to Assets Ratio | 0.93 |
| Asset Growth Rate (YoY) | -41.4% |
| Total Assets | $25.57 Million |
| Market Capitalization | $23.71 Million USD |
Valuation Analysis
Near Book Valuation: The market values Lantern Pharma Inc's assets close to their book value (0.93x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Lantern Pharma Inc's assets decreased by 41.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Lantern Pharma Inc (2018–2024)
The table below shows the annual total assets of Lantern Pharma Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $25.57 Million | -41.41% |
| 2023-12-31 | $43.65 Million | -25.82% |
| 2022-12-31 | $58.84 Million | -20.44% |
| 2021-12-31 | $73.95 Million | +263.22% |
| 2020-12-31 | $20.36 Million | +1321.19% |
| 2019-12-31 | $1.43 Million | +218.47% |
| 2018-12-31 | $449.83K | -- |
About Lantern Pharma Inc
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as gliob… Read more